Ratings by Cantor Fitzgerald (Yanni Souroutzidis)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/23/2026 | Immunic Inc. | IMUX | New Coverage | Overweight (N/A) |
7.22 (7.22) |
0% | Details | |
| 10/1/2026 | Sagimet Biosciences Inc | SGMT | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/9/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Overweight (N/A) |
10.71 (9.95) |
-7.1% | Details | |
| 8/19/2026 | Agomab Therapeutics | AGMB | New Coverage | Overweight (N/A) |
13.73 (9.26) |
-32.56% | Details | |
| 7/1/2026 | Design Therapeutics Inc | DSGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/9/2026 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2026 | Design Therapeutics Inc | DSGN | New Coverage | Overweight (N/A) |
15.61 (10.49) |
-32.8% | Details | |
| 4/1/2026 | Entrada Therapeutics | TRDA | New Coverage | Overweight (N/A) |
12.62 (4.73) |
-62.52% | Details | |
| 3/11/2026 | Satellos Bioscience Inc. | MSLE | New Coverage | Overweight (N/A) |
9.54 (6.63) |
-30.5% | Details | |
| 3/6/2026 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2026 | Karyopharm Therapeutics | KPTI | New Coverage | Overweight (N/A) |
6.55 (0.55) |
-91.6% | Details |
